Das Interesse ist hoch, auch wenn klinische Beweise fehlen
L'interesse scientifico per la formulazione orale del BPC-157 nasce da una caratteristica piuttosto insolita di questo peptide: a differenza della grande maggioranza dei peptidi, che vengono rapidamente idrolizzati dagli enzimi proteolitici del tratto gastrointestinale prima di poter essere assorbiti, il BPC-157 mostra una notevole resistenza alla degradazione enzimatica nel sugo gastrico e nell'intestino tenue
Despite picomolar activity suggesting receptor-mediated signaling, the cellular receptor for GHK-Cu has not been identified
Specifically, the FDA warns that compounded drugs containing Selank pose a risk for immunogenicity, a state in which the body perceives a substance as a threat and mounts a potentially life-threatening immune response against it.21 22 The FDA qualifies the risk to certain routes of administration but doesnt specify which routes, and also notes a lack of safety information concerning Selank administered to humans.21 Our relationships with peptide providers have given us additional insights into this topic, but the side effects theyve shared with us are no different from those of most therapeutic peptides weve covered ( injection site reactions , stomach discomfort , nausea , headaches , and dizziness )
